Functional rescue of excitatory synaptic transmission in the developing hippocampus in Fmr1-KO mouse - PubMed (original) (raw)

Functional rescue of excitatory synaptic transmission in the developing hippocampus in Fmr1-KO mouse

Rhiannon M Meredith et al. Neurobiol Dis. 2011 Jan.

Abstract

Pharmaceutical treatments are being developed to correct specific behavioural and morphological aspects of neurodevelopmental disorders such as mental retardation. Fragile X syndrome is an X-linked mental retardation with abnormal dendritic protrusions from neurons in the brain. Increased signalling via excitatory metabotropic glutamate receptor (mGluR) pathways is hypothesised to contribute to this disorder. Targeting these receptors has shown improvements in both behaviour and morphology with the Fmr1-KO mouse model for the syndrome. It is not known whether similar changes occur in excitatory synaptic activity following treatment with mGluR antagonists. We tested the effects of prolonged mGluR blockade on excitatory synaptic activity at three developmental time points in hippocampal slices. We observed a rescue effect of the antagonist MPEP upon spontaneous EPSC amplitude and charge at 2 weeks but not 1 week or 8-10 weeks of development. These data support the role of mGluR antagonist treatment for functional synaptic correction at an early developmental stage in a model for fragile X syndrome.

PubMed Disclaimer

Cited by

Hippocampal deficits in neurodevelopmental disorders.
Li Y, Shen M, Stockton ME, Zhao X. Li Y, et al. Neurobiol Learn Mem. 2019 Nov;165:106945. doi: 10.1016/j.nlm.2018.10.001. Epub 2018 Oct 12. Neurobiol Learn Mem. 2019. PMID: 30321651 Free PMC article. Review.
Longitudinal trajectories of aberrant behavior in fragile X syndrome.
Hustyi KM, Hall SS, Jo B, Lightbody AA, Reiss AL. Hustyi KM, et al. Res Dev Disabil. 2014 Nov;35(11):2691-701. doi: 10.1016/j.ridd.2014.07.003. Epub 2014 Aug 15. Res Dev Disabil. 2014. PMID: 25129200 Free PMC article.
Negative effect of treatment with mGluR5 negative allosteric modulator AFQ056 on blood biomarkers in young individuals with Fragile X syndrome.
Protic D, Breeze E, Mendoza G, Zafarullah M, Abbeduto L, Hagerman R, Coffey C, Cudkowicz M, Durbin-Johnson B, Ashwood P, Berry-Kravis E, Erickson CA, Filipink R, Gropman A, Lehwald L, Maxwell-Horn A, Morris S, Bennett AP, Prock L, Talboy A, Tartaglia N, Veenstra-VanderWeele J, Tassone F. Protic D, et al. SAGE Open Med. 2024 Sep 29;12:20503121241282401. doi: 10.1177/20503121241282401. eCollection 2024. SAGE Open Med. 2024. PMID: 39483619 Free PMC article.
Fragile X syndrome and targeted treatment trials.
Hagerman R, Lauterborn J, Au J, Berry-Kravis E. Hagerman R, et al. Results Probl Cell Differ. 2012;54:297-335. doi: 10.1007/978-3-642-21649-7_17. Results Probl Cell Differ. 2012. PMID: 22009360 Free PMC article. Review.
A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome.
Greiss Hess L, Fitzpatrick SE, Nguyen DV, Chen Y, Gaul KN, Schneider A, Lemons Chitwood K, Eldeeb MA, Polussa J, Hessl D, Rivera S, Hagerman RJ. Greiss Hess L, et al. J Dev Behav Pediatr. 2016 Oct;37(8):619-28. doi: 10.1097/DBP.0000000000000334. J Dev Behav Pediatr. 2016. PMID: 27560971 Free PMC article. Clinical Trial.

Functional rescue of excitatory synaptic transmission in the developing hippocampus in Fmr1-KO mouse - PubMed (original) (raw)